Full Year 2026 Medical Developments International Ltd Earnings Call Transcript
Key Points
- Group revenue grew 9% to $42.6 million, driven by a 21% increase in Pain Management revenue.
- Free cash flow improved significantly to $4.2 million, up $5.8 million from the prior year, with cash balances exceeding $21 million.
- Penthrox in-market demand grew across all jurisdictions, with volumes up 18% in Europe and 9% in Australia.
- Achieved key regulatory milestones, including European approval for pediatric use (from age 6) and PBS eligibility extension to nurse practitioners in Australia.
- Published a health economic study demonstrating Penthrox's cost and operational savings in hospital emergency departments, supporting commercial value proposition.
- Respiratory segment revenue declined 15% due to softer demand, particularly in the U.S., partially offset by pricing increases.
- EBIT was impacted by a $2.5 million negative swing in foreign exchange gains/losses, with a loss of $0.9 million in FY '26.
- Lower transfer prices in France and Switzerland following partner transitions reduced earnings by $1.4 million.
- The $1.1 million benefit from partner stock holdings in FY '26 is unlikely to repeat in FY '27, and working capital improvements are not expected to recur.
- Uncertainty remains from Middle East supply chain disruptions and U.S. tariffs, which could impact earnings in FY '27.
Thank you for standing by, and welcome to the Medical Developments International FY '26 Full Year Results Call. (Operator Instructions) I would now like to hand the conference over to Mr. Brent MacGregor, CEO. Please go ahead.
Thank you very much. Good morning, everyone. Welcome to today's investor briefing for our FY '26 full year results. I am Brent MacGregor, I'm the CEO, and I'm joined today by Anita James, our Chief Financial Officer. So today, I'm going to share with you an overview of our results and the company's key achievements in the year and take you through our priorities for FY '27.
Anita will speak to the financials in more detail, after which I will give some closing remarks. And then as usual, we'll have plenty of time for questions at the end of the presentation. So on that note, why don't we jump to Slide 4, and I'll walk you through the key messages we want to convey today. So in short, our strategy to grow Penthrox, it continues to gain momentum.
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
